 |
42 Diseases |  |
115 Trials |
|
115 Trials |  |
1644 News |  |
| «12345678910111213...3031» |
- doxorubicin hydrochloride / Generic mfg.
Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study (Section 20) - Mar 5, 2024 - Abstract #AACR2024AACR_7601;
DNA/DOX nanocomplexes are amenable to rigorous chemistry, manufacturing, and controls (CMC) evaluation with proven anti-cancer efficacy and improved safety profiles. Clinical trials on DNA/DOX nanocomplexes for cancer chemotherapy are warranted to fully validate their clinical utilities.
- APG-2449 / Ascentage Pharma
APG-2449, a novel focal adhesion kinase (FAK) inhibitor, inhibits metastasis and enhances the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC) (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_6725;
The combination regimen can also prolong ascites-free and survival times, as shown in the ID8-Luc peritoneal syngeneic model. These promising results support future clinical development of this combination treatment for ovarian cancer.
- Pinorubin (pirarubicin) / Sanofi
TXB-001 is an upgraded conjugated anthracycline that targets tumors with reduced risk of cardiotoxicity, hand-foot syndrome and alopecia (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_2708;
These promising results support future clinical development of this combination treatment for ovarian cancer. TXB-001 is a well-optimized N-(2-hydroxypropyl)methacrylamide copolymer-based conjugated pirarubicin (THP) and a novel candidate for developing anticancer drugs...Hand-foot syndrome (HFS) is a dose-limiting AE of DOXIL
- | Avastin (bevacizumab) / Roche
New trial, Surgery: SCENIC: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2024
P=N/A, N=18, Recruiting, Sponsor: The University of Hong Kong
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Polyethylene glycol (PEG) as a broad applicability marker for LC-MS/MS-based biodistribution analysis of nanomedicines. (Pubmed Central) - Mar 4, 2024
TXB-001 is a well-optimized N-(2-hydroxypropyl)methacrylamide copolymer-based conjugated pirarubicin (THP) and a novel candidate for developing anticancer drugs...Hand-foot syndrome (HFS) is a dose-limiting AE of DOXIL Method versatility was demonstrated by applying it to a wide variety of PEGylated compounds, including polymeric poly(ethylbutyl cyanoacrylate) (PEBCA) nanoparticles, lipidic nanoparticles (Doxil
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Pre-mixing of omega-3 fatty acid-containing liposomes enhances the drug release rate and therapeutic efficacy of anticancer drugs loaded in liposomes. (Pubmed Central) - Mar 4, 2024
Collectively, the data provide preliminary evidence that the Omega-L-triggered drug release that occurs before and after dosing, particularly at tumor site, improved the therapeutic efficacy of Caelyx. The simple approach describe here could enhance the therapeutic value of Caelyx and other anticancer drug-loaded liposomes.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (clinicaltrials.gov) - Mar 4, 2024
P3, N=800, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The simple approach describe here could enhance the therapeutic value of Caelyx and other anticancer drug-loaded liposomes. Recruiting --> Active, not recruiting
- | Journal: Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy. (Pubmed Central) - Mar 1, 2024
Recruiting --> Active, not recruiting To mitigate the Camptothesome-induced IDO1 negative feedback mechanism, we had co-encapsulated, indoximod (IND, IDO1 inhibitor) into Camptothesome using doxorubicin-derived IND (DOX-IND)...This optimum DOX-IND/Camptothesome outperformed the combination of Camptothesome, Doxil and IND or other IDO1 inhibitors (BMS-986205 or epacadostat) in treating mice bearing late-stage MC38 tumors, and combination with immune checkpoint blockade (ICB) enabled it to eradicate 60
- | pegylated liposomal doxorubicin / Generic mfg.
Journal, Checkpoint inhibition, Immunogenic cell death, Checkpoint block: Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade. (Pubmed Central) - Feb 24, 2024
We confirmed that targeting FAK by IN10018 can enhance the ICD of PLD/doxorubicin, further benefiting the anti-tumor effect of ICB. The animal tests of the triplet regimen warrant further discovery in the real world.
- pegylated liposomal doxorubicin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Pulmonary Kaposi Sarcoma Without Endobronchial Lesions in a 48-year-old Immunocompromised Male With Acute Respiratory Distress Syndrome (ARDS) (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4069;
For those with symptomatic pulmonary disease, pegylated liposomal doxorubicin has a 45% response rate even without HAART. This case serves as an emphasis for KS to remain on the differential for patients with HIV who present with pulmonary concerns with or without typical cutaneous lesions of KS, particularly in those patients in who empiric steroids are started.
- pegylated liposomal doxorubicin / Generic mfg.
Metastatic Angiosarcoma From Scalp Presenting as Bilateral Spontaneous Pneumothorax: A Case Report (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_2248;
Patient started on Doxil of which completed 2 doses while inpatient...or pneumothorax. Aggressive treatment is needed for better prognosis and CT evaluation is required for early identification of cystic like lesion.
- bictegravir (GS-9883) / Gilead, Avastin (bevacizumab) / Roche
Recurrent Chylothorax as a Manifestation of Pleural Kaposi Sarcoma (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1474;
Other potential newer therapies include interferon-alpha, mTOR inhibitors such as rapamycin or angiogenesis inhibitors such as lenalidomide, bevacizumab, sunitinib or sorafenib...Chylothorax was traditionally considered a contraindication for the utilization of tunneled pleural catheter (TPC) due to potential nutritional, immunologic and hemodynamic complications, but newer data has shown TPC to be safe in this context [1,2]. In our patient, pleurodesis may have been unable to mount an immune-inflammatory response due to leukopenia and chemotherapy.
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - Feb 19, 2024
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In our patient, pleurodesis may have been unable to mount an immune-inflammatory response due to leukopenia and chemotherapy. Recruiting --> Active, not recruiting
- pegylated liposomal doxorubicin / Generic mfg.
Clinicopathologic and Molecular Correlates to Neoadjuvant Chemotherapy (NACT) Pathologic Response in Breast Angiosarcoma (AS) (BCC Ballroom (400 Level)) - Feb 18, 2024 - Abstract #USCAP2024USCAP_1224;
NACT pathologic response in breast AS is heterogeneous, showing even distribution between good/ poor responders, and does not correlate with outcome or specific genomic alterations. Similar to other AS clinical subsets, the 5-year OS for NACT-AS was poor (19%) and related to tumor size, multifocality, and metastasis.
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Trial completion date, Trial primary completion date, Combination therapy: Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov) - Feb 15, 2024
P1, N=33, Recruiting, Sponsor: Medical College of Wisconsin
Similar to other AS clinical subsets, the 5-year OS for NACT-AS was poor (19%) and related to tumor size, multifocality, and metastasis. Trial completion date: May 2028 --> May 2026 | Trial primary completion date: May 2027 --> May 2026
- |||| Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: EPIK-O: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (clinicaltrials.gov) - Feb 15, 2024
P3, N=358, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2028 --> May 2026 | Trial primary completion date: May 2027 --> May 2026 Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, Metastases: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=36, Recruiting, Sponsor: Medical College of Wisconsin
Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
- | Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Phase classification, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=264, Completed, Sponsor: ImmunoGen, Inc.
Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025 Phase classification: P1b/2 --> P1/2
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars. (Pubmed Central) - Feb 15, 2024
Using an in vitro-in vivo rank-order relationship for doxorubicin nanoformulations, we defined in vitro release specifications for Doxil/Caelyx-like follow-on products...Furthermore, a virtual safe space was established, providing crucial insights into expected disposition kinetics and informing formulation development. By addressing bottlenecks in biopharmaceutics and formulation screening, our research advances the translation of nanomedicine from bench to bedside.
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: A Microfluidic Platform for Evaluating the Internalization of Liposome Drug Carriers in Tumor Spheroids. (Pubmed Central) - Feb 15, 2024
The utility of the microfluidic platform was validated by evaluating the efficacy of clinically approved doxorubicin-loaded liposomes (Doxil), which exhibited superior retention in the spheroids under flow conditions, in comparison with free doxorubicin. This MF platform can serve as an in vitro model for screening the efficacy of drugs encapsulated in liposomes and find applications for screening other types of nanoparticle carriers for vaccine delivery, diagnostics, and skincare.
- Zejula (niraparib) / GSK, J&J
Multicenter Real-Life Data Of Subsequent Chemotherapy After Progression To Niraparib In A Maintenance Relapse Setting (Exhibition hall) - Feb 14, 2024 - Abstract #ESGO2024ESGO_1581;
Fifty-five patients in this group received platinum-based chemotherapy and reported an ORR of 29%. The remaining 16 women with PFI >6 months were treated with pegylated liposomal doxorubicin (PLD) in combination with trabectedin: no responses were reported in this cohort of patients.Conclusion Patients who experienced disease progression following niraparib treatment showed a poor response to subsequent platinum-based chemotherapy, even when progression occurred more than 6 months after completion of their penultimate platinum-based chemotherapy.
- The Predictive Role Of Platinum-Based Chemotherapy Combinations On The Effectiveness Of PARP-Inhibitors As Maintenance Therapy In The Platinum-Sensitive Recurrent Ovarian Cancer: An Observational MITO Study (Exhibition hall) - Feb 14, 2024 - Abstract #ESGO2024ESGO_1579;
The remaining 16 women with PFI >6 months were treated with pegylated liposomal doxorubicin (PLD) in combination with trabectedin: no responses were reported in this cohort of patients.Conclusion Patients who experienced disease progression following niraparib treatment showed a poor response to subsequent platinum-based chemotherapy, even when progression occurred more than 6 months after completion of their penultimate platinum-based chemotherapy. Introduction/Background State of the art therapy for recurrent platinum sensitive and PARP inhibitors (PARPi) na
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Phase classification, Metastases: ICON: Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (clinicaltrials.gov) - Feb 7, 2024
P2, N=82, Completed, Sponsor: Oslo University Hospital
Introduction/Background State of the art therapy for recurrent platinum sensitive and PARP inhibitors (PARPi) na Active, not recruiting --> Completed | Phase classification: P2b --> P2
- Zejula (niraparib) / GSK, J&J, Tecentriq (atezolizumab) / Roche
Subgroup Analysis By Chemotherapy Regimen In The ENGOT-Ov41/GEICO 69-O/ANITA Phase 3 Trial Evaluating Atezolizumab Combined With A Platinum Doublet And Maintenance Niraparib For Late-Relapsing Ovarian Cancer (Exhibition hall) - Feb 7, 2024 - Abstract #ESGO2024ESGO_1496;
P3
Conclusion The apparent difference in atezolizumab treatment effect according to investigator-selected chemotherapy doublet, including more favourable outcomes with atezolizumab in the gemcitabine subgroup, may be attributable to selection bias towards gemcitabine in poorer-prognosis patients and the small sample sizes of the paclitaxel and gemcitabine subgroups. Ongoing translational work may reveal further differences and hypotheses.
- || Ninlaro (ixazomib) / Takeda
Clinical, Journal: Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study. (Pubmed Central) - Feb 6, 2024
BYESS2023116) and Beijing Medical Award Foundation (No. YXJL-2018-0539-0073).
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
P3 data, Journal, BRCA Biomarker, PARP Biomarker: Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. (Pubmed Central) - Feb 5, 2024
YXJL-2018-0539-0073). Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.
- || pegylated liposomal doxorubicin / Generic mfg.
Review, Journal: Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications. (Pubmed Central) - Feb 1, 2024
Since Doxil's first clinical approval in 1995, lipid nanoparticles have garnered great interest and shown exceptional therapeutic efficacy...High biocompatibility, ease of production, scalability, non-toxicity, and tailored distribution are just a meager of the enticing allowances of using lipid nanoparticles as drug delivery vehicles. Due to the present constraints in drug delivery, more research is required to utterly realize the potential of lipid nanoparticles for possible clinical and therapeutic purposes.
- ||| elraglusib (9-ING-41) / Actuate Therap
Enrollment closed, Metastases: Actuate 1801: 9-ING-41 in Patients With Advanced Cancers (clinicaltrials.gov) - Jan 30, 2024
P2, N=350, Active, not recruiting, Sponsor: Actuate Therapeutics Inc.
Due to the present constraints in drug delivery, more research is required to utterly realize the potential of lipid nanoparticles for possible clinical and therapeutic purposes. Recruiting --> Active, not recruiting
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Zepzelca (lurbinectedin) / PharmaMar, Jazz
Review, Journal, Tumor microenvironment: Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. (Pubmed Central) - Jan 27, 2024
Finally, the novel therapeutic venues that are currently under exploration, in combination with a plethora of different immunotherapeutic strategies or specific molecular-targeted inhibitors, are reviewed, with particular emphasis on the usage of immune checkpoint inhibitors, or other bioactive molecules that have shown synergistic effects in terms of tumour regression and ablation. These approaches intend to tackle the complexity of managing cancer patients in the context of precision medicine and the application of tailor-made strategies aiming at the reduction of undesired side effects.
- | pegylated liposomal doxorubicin / Generic mfg.
Preclinical, Journal: Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice. (Pubmed Central) - Jan 26, 2024
Moreover, in C26 tumor-bearing mice, the tumor growth suppressive effects of both Doxil and Liposomal l-OHP were significantly attenuated in the presence of anti-PEG IgM antibodies induced by the topical application of cosmetic products. These results confirm that the topical application of a cosmetic product containing PEG derivatives could produce preexisting anti-PEG antibodies that then affect the therapeutic efficacy of subsequent doses of PEGylated therapeutics.
- pegylated liposomal doxorubicin / Generic mfg.
SPINDLING INTO THE HEART: UNDIFFERENTIATED SPINDLE CELL SARCOMA INVADING THE PERICARDIUM (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3310;
A clinical index of suspicion and multiple diagnostic modalities may be necessary to establish the correct diagnosis. Some patients may require emergent initiation of treatment without a definitive etiology determined.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P2b data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. (Pubmed Central) - Jan 24, 2024
P2b
The addition of ipi/nivo to chemotherapy increased toxicity without improving efficacy. Ipi/nivo administered sequentially to chemotherapy was tolerable and induced clinical responses.
- Zejula (niraparib) / GSK, J&J
Multicenter Real-Life Data Of Subsequent Chemotherapy After Progression To Niraparib In A Maintenance Relapse Setting (Exhibition hall) - Jan 18, 2024 - Abstract #ESGO2024ESGO_665;
Fifty-five patients in this group received platinum-based chemotherapy and reported an ORR of 29%. The remaining 16 women with PFI >6 months were treated with pegylated liposomal doxorubicin (PLD) in combination with trabectedin: no responses were reported in this cohort of patients.Conclusion Patients who experienced disease progression following niraparib treatment showed a poor response to subsequent platinum-based chemotherapy, even when progression occurred more than 6 months after completion of their penultimate platinum-based chemotherapy.
- The Predictive Role Of Platinum-Based Chemotherapy Combinations On The Effectiveness Of PARP-Inhibitors As Maintenance Therapy In The Platinum-Sensitive Recurrent Ovarian Cancer: An Observational MITO Study (Exhibition hall) - Jan 18, 2024 - Abstract #ESGO2024ESGO_661;
The remaining 16 women with PFI >6 months were treated with pegylated liposomal doxorubicin (PLD) in combination with trabectedin: no responses were reported in this cohort of patients.Conclusion Patients who experienced disease progression following niraparib treatment showed a poor response to subsequent platinum-based chemotherapy, even when progression occurred more than 6 months after completion of their penultimate platinum-based chemotherapy. Introduction/Background State of the art therapy for recurrent platinum sensitive and PARP inhibitors (PARPi) na
- Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Health-Related Quality Of Life In Patients With FRa Positive Platinum-Resistant Ovarian Cancer Treated With Mirvetuximab Soravtansine Vs. Investigator (Session hall III (112)) - Jan 18, 2024 - Abstract #ESGO2024ESGO_431;
Here we report quality of life (QoL) findings from the MIRASOL trial, measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 instrument.Methodology 453 patients with FR? positive PROC (Roche FOLR1-2.1 Assay) who received 1-3 prior lines of therapy were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight every 3 weeks or investigator
- || Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, Takeda
Trial completion date, Trial primary completion date: MIROVA: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FR?) High Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 16, 2024
P2, N=136, Recruiting, Sponsor: AGO Research GmbH
positive PROC (Roche FOLR1-2.1 Assay) who received 1-3 prior lines of therapy were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight every 3 weeks or investigator Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- | peposertib (M3814) / EMD Serono
Journal: DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models. (Pubmed Central) - Jan 11, 2024
These findings align with previous evidence showcasing the synergy between DNA-PK inhibition and Topo II inhibitors in diverse tumor models, including breast and ovarian cancers. Our study extends the potential utility of combined therapy to synovial sarcoma.
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Journal: MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. (Pubmed Central) - Jan 11, 2024
Regarding tolerability, no remarkable disparity was noted; PLD-Trabectedin was confirmed to be a well-tolerated scheme in both groups. To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
New P2 trial: BV-AVD-R Treatment Children Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 11, 2024
P2, N=44, Enrolling by invitation, Sponsor: Beijing Children's Hospital
- | Trial completion date, Trial primary completion date, Combination therapy: NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - Jan 11, 2024
P2, N=149, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape. Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2023
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
P3 data, Retrospective data, Review, Journal, BRCA Biomarker: Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials. (Pubmed Central) - Jan 8, 2024
Trabectedin combined with PLD significantly improves OS and PFS in patients with BRCA-associated and platinum-sensitive recurrent ovarian cancers. The potential use of trabectedin combined with PLD should be selected according to the PFI and BRCA mutation status of patients.
- || albumin-bound paclitaxel / Generic mfg.
P2 data, Journal: A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer. (Pubmed Central) - Jan 8, 2024
P2
The potential use of trabectedin combined with PLD should be selected according to the PFI and BRCA mutation status of patients. Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD/C/HP-nabP/HP, suggesting a potential therapeutic option in HER2-positive BC.
- | Avastin (bevacizumab) / Roche, Jemperli (dostarlimab-gxly) / GSK
Trial initiation date: A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (clinicaltrials.gov) - Jan 5, 2024
P2, N=198, Not yet recruiting, Sponsor: Yonsei University
Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD/C/HP-nabP/HP, suggesting a potential therapeutic option in HER2-positive BC. Initiation date: Sep 2023 --> Jan 2024
- | Talidox (doxorubicin liposomal) / Innomedica
Trial completion date, Trial primary completion date, Metastases: SAKK 65/16: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 31, 2023
P1, N=30, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- | Enrollment open, Metastases: ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov) - Dec 29, 2023
P2, N=252, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Initiation date: Sep 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- ATRC-101 / Atreca
Phase classification, Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (clinicaltrials.gov) - Dec 28, 2023
P1, N=87, Terminated, Sponsor: Atreca, Inc.
Not yet recruiting --> Recruiting Phase classification: P1b --> P1 | N=240 --> 87 | Trial completion date: Mar 2025 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Nov 2023; Sponsor Decision
- | pegylated liposomal doxorubicin / Generic mfg.
Retrospective data, Journal: Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre. (Pubmed Central) - Dec 26, 2023
RIA has high rates of recurrence and mortality and appears to be occurring sooner after breast radiotherapy. Further studies on its pathogenesis and effective treatment are warranted.
- | pegylated liposomal doxorubicin / Generic mfg.
Trial primary completion date, Combination therapy: Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov) - Dec 22, 2023
P1/2, N=72, Not yet recruiting, Sponsor: Sham Sunder Kakar
Further studies on its pathogenesis and effective treatment are warranted. Trial primary completion date: Nov 2024 --> Nov 2025
- | peposertib (M3814) / EMD Serono
Enrollment open, Trial initiation date, Combination therapy, Metastases: ETCTN 10563: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (clinicaltrials.gov) - Dec 20, 2023
P1, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2024 --> Nov 2025 Suspended --> Recruiting | Initiation date: May 2023 --> Feb 2024
- |||||| defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
Enrollment open, Combination therapy: LGSOC: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Dec 19, 2023
P3, N=270, Recruiting, Sponsor: Verastem, Inc.
Suspended --> Recruiting | Initiation date: May 2023 --> Feb 2024 Not yet recruiting --> Recruiting